




ZYMEWIRE™

Biopharma Recap




Q3 2024

Cumulative Funding by Region (Q3 '23 vs. '24)




Funding by Employee Range Groups (2024 YTD)

The numbers on top of each bar indicate the number of companies represented and the percentage of total funding they account for




Cumulative Funding by Therapeutic Area (Top 10) - 2024 YTD


The numbers on top of each bar indicate the number of companies represented and the percentage of total funding they account for




Study Initiations by Phase (Q3 '23 vs. '24)




Study Closeouts by Phase (Q3 '23 vs. '24)




North America: Upcoming Clinical Trials by Phase (Q3 '23 vs. '24)




Europe: Upcoming Clinical Trials by Phase (Q3 '23 vs. '24)




APAC: Upcoming Clinical Trials by Phase (Q3 '23 vs. '24)




Gene Therapies: Upcoming Clinical Trials by Phase (Q3 '23 vs. '24)



Cell Therapies: Upcoming Clinical Trials by Phase (Q3 '23 vs. '24)



Number of Active Biotechs in Q3 2024 - by Highest Phase



Number of Newly Identified Biotechs (Q3 '23 vs. '24)

